GO:0120508 GDP-mannose pyrophosphorylase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120508 describes the GDP-mannose pyrophosphorylase complex, the enzyme machine that converts GTP and mannose-1-phosphate into GDP-mannose, the activated sugar donor used in mannosylation reactions.
• In humans the complex is a heterodimer of a catalytic beta subunit (GMPPB) and a regulatory alpha subunit (GMPPA); in most bacteria it is a homodimer.
• GMPPA acts as a regulatory subunit that controls GDP-mannose homeostasis and prevents excessive accumulation of the sugar nucleotide.
• Biallelic GMPPB mutations cause GMPPB-CDG, a congenital disorder of glycosylation with muscular dystrophy, α-dystroglycan hypoglycosylation, and lysosomal dysfunction [3,7].
• GMPPA defects cause a distinct neuromuscular disorder characterized by α-dystroglycan hyperglycosylation, showing that both loss and gain of GDP-mannose levels are pathogenic.
• The complex is a validated drug and crop-protection target in pathogens such as Trypanosoma brucei, Helicobacter pylori, and Sclerotinia sclerotiorum [2,4,5].
Description
GDP-mannose pyrophosphorylase complex (GO:0120508) is a cellular component defined as a protein complex capable of catalyzing the reaction of GTP and mannose-1-phosphate to form GDP-mannose. GDP-mannose is the universal activated donor for mannose incorporation into glycoconjugates, and its availability controls the mannosylation status of proteins and lipids in the secretory pathway [1,6]. Because the complex sits at the entry point of GDP-mannose biosynthesis, its activity directly influences endoplasmic reticulum (ER) and Golgi glycosylation capacity [1,6]. In humans, the complex is a heterodimer composed of a catalytic beta subunit (GMPPB) and a regulatory alpha subunit (GMPPA). The regulatory subunit is not merely a scaffold: structural and biochemical work has shown that GMPPA controls GDP-mannose homeostasis by feedback inhibition, preventing uncontrolled sugar-nucleotide accumulation. In most bacteria, by contrast, the enzyme functions as a homodimer, and in some pathogens it is fused to phosphomannose isomerase as a bifunctional enzyme [1,4]. The biomedical importance of GO:0120508 is now firmly established: mutations in GMPPB cause a congenital disorder of glycosylation with dystroglycanopathy and lysosomal dysfunction [3,7], while GMPPA defects cause a mirror-image neuromuscular disorder with α-dystroglycan hyperglycosylation. Beyond human disease, the complex is essential in the bloodstream form of Trypanosoma brucei and is a promising target for host-induced gene silencing in plant fungal pathogens [2,5]. Researchers therefore study GO:0120508 to understand glycosylation homeostasis, neuromuscular disease mechanisms, and anti-pathogen strategies [1,2,3,5,7].
GDP-mannose pyrophosphorylase complex At A Glance
| GO ID | GO:0120508 |
|---|---|
| GO term | GDP-mannose pyrophosphorylase complex |
| Ontology | cellular_component |
| Synonym | GMPPA-GMPPB complex |
| Major function | Catalyzes GTP + mannose-1-phosphate to GDP-mannose |
| Subunit architecture | Homodimer in most bacteria; heterodimer in most eukaryotes |
| Human subunits | Catalytic beta subunit GMPPB; regulatory alpha subunit GMPPA |
| Pathogen relevance | Essential in Trypanosoma brucei; drug target in Helicobacter pylori and Sclerotinia sclerotiorum |
What Is GO:0120508?
GO:0120508 (GDP-mannose pyrophosphorylase complex) is a protein complex that catalyzes the formation of GDP-mannose from GTP and mannose-1-phosphate. The complex is a homodimer in most bacteria and a heterodimer in most eukaryotes; in humans it consists of a catalytic beta subunit (GMPPB) and a regulatory alpha subunit (GMPPA). The synonym GMPPA-GMPPB complex reflects this human heterodimeric architecture.
Why Is GDP-mannose pyrophosphorylase complex Important in Cell Biology?
GO:0120508 is important because it defines the enzyme complex that sets the rate of GDP-mannose supply for all mannosylation reactions in the secretory pathway. GDP-mannose is required for N-glycosylation, O-mannosylation, glycosylphosphatidylinositol anchor synthesis, and α-dystroglycan glycosylation, so the complex influences protein folding, ER and Golgi function, and cell-matrix adhesion [1,6,7]. In humans, mutations in GMPPB cause GMPPB-CDG with muscular dystrophy and lysosomal dysfunction, while GMPPA mutations cause a neuromuscular disorder with α-dystroglycan hyperglycosylation, demonstrating that both decreased and increased GDP-mannose levels are pathogenic [3,7]. In pathogens, the complex is essential for viability or virulence, making it a validated target for antiprotozoal, antibacterial, and antifungal strategies [2,4,5].
• Defines the enzyme complex that produces GDP-mannose, the activated mannose donor for glycosylation.
• Controls ER and Golgi mannosylation capacity and secretory pathway homeostasis [1,6].
• GMPPB mutations cause GMPPB-CDG with muscular dystrophy, α-dystroglycan hypoglycosylation, and lysosomal dysfunction [3,7].
• GMPPA mutations cause a neuromuscular disorder with α-dystroglycan hyperglycosylation.
• The complex is essential in the bloodstream form of Trypanosoma brucei.
• Bifunctional phosphomannose isomerase/GDP-mannose pyrophosphorylase controls GDP-mannose biosynthesis in Helicobacter pylori.
• GDP-mannose-1-phosphate guanylyltransferase is a potential host-induced gene silencing target against Sclerotinia sclerotiorum.
• Hypermannosylation alters ER and Golgi structure and function, linking the complex to organelle biology.
• The complex is a tractable target for small-molecule and genetic validation in infectious disease [2,4,5].
• Provides a model system for studying enzyme complex assembly and allosteric regulation.
What Happens During GDP-mannose pyrophosphorylase complex?
Substrate binding and catalysis
In simple terms: The enzyme grabs GTP and mannose-1-phosphate and joins them together to make GDP-mannose.
The GDP-mannose pyrophosphorylase complex catalyzes the reaction of GTP and mannose-1-phosphate to form GDP-mannose. In humans, the catalytic beta subunit GMPPB provides the active site, while the regulatory alpha subunit GMPPA modulates activity. In bacteria, the homodimeric enzyme performs the same reaction, and in pathogens such as Helicobacter pylori the activity is fused to phosphomannose isomerase as a bifunctional enzyme that serves as the point of control for GDP-D-mannose biosynthesis.
GDP-mannose homeostasis and feedback control
In simple terms: The complex has a built-in brake so the cell does not make too much GDP-mannose.
Cryo-EM structures of the human GMPPA-GMPPB complex revealed how cells maintain GDP-mannose homeostasis. GMPPA acts as a regulatory subunit that senses GDP-mannose levels and inhibits the catalytic activity of GMPPB, preventing excessive accumulation of the sugar nucleotide. This feedback mechanism is critical because both loss and gain of GDP-mannose levels cause disease: GMPPB defects reduce GDP-mannose and cause hypoglycosylation, whereas GMPPA defects increase GDP-mannose and cause hyperglycosylation [1,7].
Supply of GDP-mannose to the secretory pathway
In simple terms: The GDP-mannose made by the complex is delivered to the ER and Golgi for attaching mannose to proteins and lipids.
GDP-mannose produced by the complex is used in the ER and Golgi for N-glycosylation, O-mannosylation, and glycosylphosphatidylinositol anchor synthesis [1,6]. Perturbations in GDP-mannose supply alter the structure and functionality of the ER and Golgi complex, as shown by hypermannosylation studies. In humans, adequate GDP-mannose is required for α-dystroglycan glycosylation, and GMPPB mutations cause α-dystroglycan hypoglycosylation with muscular dystrophy.
Role in pathogen viability and virulence
In simple terms: Many pathogens need this complex to survive, which makes it a good drug target.
GDP-mannose pyrophosphorylase is essential in the bloodstream form of Trypanosoma brucei, validating the complex as a potential antiprotozoal target. In Helicobacter pylori, the bifunctional phosphomannose isomerase/GDP-D-mannose pyrophosphorylase is the point of control for GDP-D-mannose biosynthesis. In the plant fungal pathogen Sclerotinia sclerotiorum, a GDP-mannose-1-phosphate guanylyltransferase is a potential host-induced gene silencing target.
Disease mechanisms: GMPPB-CDG and GMPPA-related disorder
In simple terms: When the complex is broken, muscles and nerves are affected because glycosylation goes wrong.
GMPPB-CDG results in lysosomal dysfunction and acid alpha-glucosidase deficiency, linking the complex to lysosomal biology. GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation, showing that the regulatory subunit is essential for normal glycosylation. Together, these findings establish GO:0120508 as a central node in glycosylation-related neuromuscular disease [3,7].
Key Genes Involved in GO:0120508 GDP-mannose pyrophosphorylase complex
The following genes and proteins are the principal components and regulators of the GDP-mannose pyrophosphorylase complex (GO:0120508) and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GMPPB | Catalytic beta subunit of the human GDP-mannose pyrophosphorylase complex | Mutations cause GMPPB-CDG with muscular dystrophy and lysosomal dysfunction [3,7] |
| GMPPA | Regulatory alpha subunit of the human complex | Mutations cause neuromuscular disorder with α-dystroglycan hyperglycosylation |
| PMM2 | Phosphomannomutase 2, supplies mannose-1-phosphate to the complex | Congenital disorder of glycosylation model for GDP-mannose pathway |
| MPI | Phosphomannose isomerase, upstream of mannose-1-phosphate | Bifunctional with GDP-mannose pyrophosphorylase in Helicobacter pylori |
| DPM1 | Dolichol-phosphate mannosyltransferase, uses GDP-mannose | Downstream consumer of GDP-mannose in ER glycosylation |
| ALG1 | Mannosyltransferase using GDP-mannose in N-glycan assembly | Links GDP-mannose supply to N-glycosylation |
| POMT1 | Protein O-mannosyltransferase 1, uses GDP-mannose | α-dystroglycan O-mannosylation affected in dystroglycanopathies |
| POMT2 | Protein O-mannosyltransferase 2, uses GDP-mannose | α-dystroglycan O-mannosylation affected in dystroglycanopathies |
| DAG1 | Dystroglycan, the major O-mannosylated protein | Readout for GDP-mannose-dependent glycosylation |
| GAA | Acid alpha-glucosidase, lysosomal enzyme | Deficient in GMPPB-CDG lysosomal dysfunction |
| TbGMPP | Trypanosoma brucei GDP-mannose pyrophosphorylase | Essential in bloodstream form, drug target |
| HpPMI-GMPP | Helicobacter pylori bifunctional phosphomannose isomerase/GDP-mannose pyrophosphorylase | Point of control for GDP-D-mannose biosynthesis |
| SsGMPP | Sclerotinia sclerotiorum GDP-mannose-1-phosphate guanylyltransferase | HIGS target for crop protection |
| GMPPA-GMPPB heterodimer | Functional human enzyme complex | Structural and regulatory studies by cryo-EM |
| GDP-mannose | Product of the complex, activated mannose donor | Central metabolite for glycosylation [1,6] |
| GTP | Substrate of the complex | Cofactor in GDP-mannose synthesis |
| Mannose-1-phosphate | Substrate of the complex | Rate-limiting metabolite in GDP-mannose biosynthesis [1,4] |
| ER/Golgi glycosylation machinery | Consumes GDP-mannose for protein and lipid glycosylation | Affected by hypermannosylation |
How Is GDP-mannose pyrophosphorylase complex Regulated?
The GDP-mannose pyrophosphorylase complex is regulated by its own product: GMPPA senses GDP-mannose and inhibits the catalytic activity of GMPPB, providing feedback control of GDP-mannose homeostasis. This regulatory mechanism ensures that GDP-mannose levels are maintained within a narrow range, because both deficiency and excess cause disease [1,7]. In bacteria, the bifunctional phosphomannose isomerase/GDP-mannose pyrophosphorylase is the point of control for GDP-D-mannose biosynthesis, integrating upstream mannose flux with downstream demand. In eukaryotes, the complex is also influenced by the availability of mannose-1-phosphate, which is supplied by phosphomannomutase and phosphomannose isomerase [1,4].
GDP-mannose pyrophosphorylase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GMPPB | GMPPB-CDG with muscular dystrophy, α-dystroglycan hypoglycosylation, lysosomal dysfunction | GMPPB knockout or point-mutation human cell lines; patient fibroblasts [3,7] |
| GMPPA | Neuromuscular disorder with α-dystroglycan hyperglycosylation | GMPPA knockout or point-mutation cell models |
| TbGMPP | Trypanosoma brucei viability | Trypanosome knockout or RNAi models |
| HpPMI-GMPP | Helicobacter pylori GDP-mannose biosynthesis | Bacterial knockout and biochemical assays |
| SsGMPP | Sclerotinia sclerotiorum virulence | Host-induced gene silencing in plant models |
GMPPB-CDG: congenital disorder of glycosylation with muscular dystrophy
Biallelic mutations in GMPPB cause GMPPB-CDG, a congenital disorder of glycosylation characterized by muscular dystrophy and α-dystroglycan hypoglycosylation [3,7]. Recent work shows that GMPPB-CDG results in lysosomal dysfunction and acid alpha-glucosidase deficiency, expanding the disease phenotype beyond the neuromuscular system. These findings link GO:0120508 directly to lysosomal biology and suggest that GDP-mannose deficiency impairs multiple glycosylation-dependent pathways.
GMPPA-related neuromuscular disorder with α-dystroglycan hyperglycosylation
GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation, demonstrating that loss of the regulatory subunit leads to excessive GDP-mannose and abnormal glycosylation. This mirror-image mechanism contrasts with GMPPB deficiency and highlights the importance of balanced GDP-mannose homeostasis for muscle and nerve function [1,7].
Infectious disease and antipathogen targeting
GDP-mannose pyrophosphorylase is essential in the bloodstream form of Trypanosoma brucei, making it a candidate drug target for African trypanosomiasis. In Helicobacter pylori, the bifunctional enzyme controls GDP-D-mannose biosynthesis and is a potential antibacterial target. In the plant pathogen Sclerotinia sclerotiorum, a GDP-mannose-1-phosphate guanylyltransferase is a potential host-induced gene silencing target for crop protection.
ER and Golgi dysfunction in glycosylation disorders
Hypermannosylation alters the structure and functionality of the ER and Golgi complex, indicating that GDP-mannose levels influence organelle homeostasis. Because the complex supplies GDP-mannose to these organelles, its dysfunction can perturb secretory pathway function and contribute to disease phenotypes [1,6].
From GDP-mannose pyrophosphorylase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GMPPB reduce GDP-mannose and cause hypoglycosylation? | GMPPB knockout cell line [3,7] |
| Does a specific GMPPB missense mutation impair catalysis? | GMPPB point-mutation knock-in [3,7] |
| Does GMPPA feedback inhibition require GDP-mannose binding? | GMPPA point-mutation knock-in |
| Can tagged GMPPB be used to purify the complex? | Tagged knock-in of GMPPB |
| Does overexpression of GMPPA alter glycosylation? | GMPPA overexpression cell line [1,7] |
| Is the complex essential in a pathogen? | Pathogen knockout or RNAi [2,4,5] |
How to Study the GDP-mannose pyrophosphorylase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | Three-dimensional structure of the GMPPA-GMPPB complex | Understanding subunit architecture and regulation |
| Enzymatic assay | GDP-mannose pyrophosphorylase activity | Validating mutations and inhibitors [1,4] |
| Lectin blotting | Protein mannosylation status | Detecting hypoglycosylation or hypermannosylation [6,7] |
| Mass spectrometry | Glycan structures and site occupancy | Profiling glycosylation changes |
| CRISPR knockout | Gene essentiality and phenotype | Testing GMPPB and GMPPA function [3,7] |
| RNAi / HIGS | Gene silencing in pathogens | Target validation in Trypanosoma and Sclerotinia [2,5] |
| Immunofluorescence | Subcellular localization of complex subunits | ER and Golgi localization studies [1,6] |
| Metabolomics | GDP-mannose and related nucleotide sugars | Measuring homeostasis |
Structural biology (cryo-EM) of the GMPPA-GMPPB complex
Cryo-EM structures of the human GMPPA-GMPPB complex revealed the architecture of the heterodimer and the mechanism of GDP-mannose homeostasis. Structural studies are essential for understanding how GMPPA regulates GMPPB and how disease mutations affect complex assembly and catalysis.
Biochemical assays of GDP-mannose pyrophosphorylase activity
Enzymatic assays measuring the conversion of GTP and mannose-1-phosphate to GDP-mannose are used to validate the catalytic activity of the complex and the effects of mutations [1,4]. Such assays are also used to test inhibitors in pathogen targets such as Trypanosoma brucei and Helicobacter pylori [2,4].
Glycosylation profiling and lectin blotting
Changes in GDP-mannose levels alter protein mannosylation, which can be monitored by lectin blotting and mass spectrometry [6,7]. Hypermannosylation of ER and Golgi proteins is a readout for increased GDP-mannose, while α-dystroglycan hypoglycosylation is a readout for decreased GDP-mannose [6,7].
Genetic and CRISPR screens in model organisms
Knockout and point-mutation models in human cells, Trypanosoma brucei, Helicobacter pylori, and Sclerotinia sclerotiorum have been used to test the essentiality and druggability of the complex [2,3,4,5]. CRISPR-based screens can identify modifiers of GDP-mannose homeostasis and glycosylation [1,3].
How CRISPR Can Be Used to Study GO:0120508 GDP-mannose pyrophosphorylase complex
Knockout
CRISPR knockout of GMPPB or GMPPA in human cell lines can model the loss-of-function phenotypes of GMPPB-CDG and GMPPA-related disorder, including α-dystroglycan hypoglycosylation or hyperglycosylation and lysosomal dysfunction [3,7]. Knockout of pathogen orthologs can validate essentiality in Trypanosoma brucei and other pathogens.
Point Mutation
CRISPR point-mutation knock-in can introduce patient-specific missense mutations into GMPPB or GMPPA to dissect catalytic versus regulatory functions [1,3,7]. Such models are valuable for testing whether a variant affects GDP-mannose homeostasis or complex assembly.
Knock-in
Tagged knock-in of GMPPB or GMPPA enables affinity purification and imaging of the endogenous complex. Knock-in of reporter or degron tags can be used to study complex dynamics and turnover.
Overexpression
Overexpression of GMPPA or GMPPB can be used to test gain-of-function effects on GDP-mannose levels and glycosylation [1,7]. Overexpression models complement knockout studies by revealing the consequences of excess complex activity.
How EDITGENE Supports GDP-mannose pyrophosphorylase complex Research
Researchers studying GDP-mannose pyrophosphorylase complex-related genes often need to determine whether a candidate gene is causally involved in glycosylation homeostasis, neuromuscular disease, or pathogen viability. EDITGENE provides the full spectrum of CRISPR cell-model engineering services to support such studies, from knockout to precise point mutations and tagged knock-ins.
Contact EDITGENE today to design your custom CRISPR model for GDP-mannose pyrophosphorylase complex research.
Frequently Asked Questions About GDP-mannose pyrophosphorylase complex
What is GO:0120508?
GO:0120508 is the Gene Ontology cellular component term for the GDP-mannose pyrophosphorylase complex, an enzyme complex that catalyzes the formation of GDP-mannose from GTP and mannose-1-phosphate.
What is the GDP-mannose pyrophosphorylase complex?
It is a protein complex that produces GDP-mannose, the activated mannose donor used in glycosylation; it is a homodimer in most bacteria and a heterodimer in most eukaryotes.
What genes are involved in the GDP-mannose pyrophosphorylase complex?
In humans, the complex is composed of the catalytic beta subunit GMPPB and the regulatory alpha subunit GMPPA.
What does GMPPB do?
GMPPB is the catalytic beta subunit of the human GDP-mannose pyrophosphorylase complex, and its mutations cause GMPPB-CDG with muscular dystrophy and lysosomal dysfunction [3,7].
What does GMPPA do?
GMPPA is the regulatory alpha subunit that controls GDP-mannose homeostasis by feedback inhibition of GMPPB.
What diseases are linked to the GDP-mannose pyrophosphorylase complex?
Mutations in GMPPB cause GMPPB-CDG with muscular dystrophy and lysosomal dysfunction, while GMPPA mutations cause a neuromuscular disorder with α-dystroglycan hyperglycosylation [3,7].
Why is GDP-mannose important?
GDP-mannose is the activated mannose donor required for N-glycosylation, O-mannosylation, and glycosylphosphatidylinositol anchor synthesis in the ER and Golgi [1,6].
Is the GDP-mannose pyrophosphorylase complex a drug target?
Yes, it is essential in Trypanosoma brucei and is a potential target in Helicobacter pylori and Sclerotinia sclerotiorum [2,4,5].
How is the GDP-mannose pyrophosphorylase complex regulated?
GMPPA senses GDP-mannose and inhibits GMPPB, providing feedback control of GDP-mannose homeostasis.
How can I study the GDP-mannose pyrophosphorylase complex with CRISPR?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models can be used to dissect the function of GMPPB and GMPPA in glycosylation and disease [1,3,7].
Conclusion
GO:0120508 (GDP-mannose pyrophosphorylase complex) is a central enzyme machine in glycosylation biology, converting GTP and mannose-1-phosphate into GDP-mannose. Its human heterodimeric form, composed of GMPPB and GMPPA, is essential for maintaining GDP-mannose homeostasis, and mutations in either subunit cause distinct neuromuscular and glycosylation disorders [1,3,7]. The complex is also a validated target in pathogens, underscoring its broad biomedical relevance [2,4,5]. CRISPR-based cell models and biochemical assays provide powerful tools to dissect its mechanism and disease connections [1,3,7].
References
- 1. Zheng L et al.. 2021. Cryo-EM structures of human GMPPA-GMPPB complex reveal how cells maintain GDP-mannose homeostasis.. Nat Struct Mol Biol 28(5):1-12 PMID: 33986552
- 2. Denton H et al.. 2010. GDP-mannose pyrophosphorylase is essential in the bloodstream form of Trypanosoma brucei.. Biochem J 425(3):603-14 PMID: 19919534
- 3. Damiano C et al.. 2026. GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.. J Inherit Metab Dis 49(1):e70136 PMID: 41554119
- 4. Wu B et al.. 2002. Bifunctional phosphomannose isomerase/GDP-D-mannose pyrophosphorylase is the point of control for GDP-D-mannose biosynthesis in Helicobacter pylori.. FEBS Lett 519(1-3):87-92 PMID: 12023023
- 5. Zhang C et al.. 2025. A GDP-mannose-1-phosphate guanylyltransferase as a potential HIGS target against Sclerotinia sclerotiorum.. PLoS Pathog 21(5):e1013129 PMID: 40315235
- 6. Franzka P et al.. 2023. Impact of Hypermannosylation on the Structure and Functionality of the ER and the Golgi Complex.. Biomedicines 11(1) PMID: 36672654
- 7. Franzka P et al.. 2021. GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation.. J Clin Invest 131(9) PMID: 33755596
